Valsartan Capsules

This product is an antagonist of angiotensin II (Ang II) receptor AT1. It inhibits vasoconstriction and the release of aldosterone by selectively blocking the binding of Ang II to AT1 receptor, thus producing a hypotensive effect.

Valsartan.

This product is a hard capsule, and the contents are white powder.

Valsartan is suitable for all types of mild to moderate hypertension, especially for patients who are intolerant to ACE inhibitors.

1. The recommended dose is 80 mg, once a day, regardless of gender, age and race. The antihypertensive effect appears within 2 weeks, and the maximum effect is reached after 4 weeks. For patients who fail to adequately control blood pressure, the daily dose can be increased to 160 mg or a diuretic can be added. This drug can be used in combination with other antihypertensive preparations. 2. No dose adjustment is required for patients with mild to moderate renal impairment or non-biliary and non-cholestatic liver dysfunction. 3. No dose adjustment is required for elderly patients. 4. There is no safety and efficacy data for pediatric patients. 5. When hypertensive patients take this drug, their heart rate will not be affected while their blood pressure drops. 6. When this drug is suddenly discontinued, there will be no blood pressure rebound and other clinical adverse reactions. 7. Multiple doses of this drug have no significant effect on total cholesterol, fasting triglycerides, fasting blood glucose and uric acid.

1. The overall incidence of adverse reactions of this drug is similar to that of the placebo group. The main adverse reactions observed in clinical applications are: headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, back pain, nausea, pharyngitis and joint pain. The incidence of adverse reactions is not related to the dose and duration of treatment, and is not related to gender, age or race. It is not yet known whether this reaction is causally related to the treatment of this product. 2. Laboratory indicators: This drug may occasionally cause a decrease in hemoglobin and hematocrit. In clinical controlled trials, patients taking this drug had a significant decrease in hematocrit and hemoglobin, which were 0.8% and 0.4% respectively, and 0.1% in the placebo group. The incidence of neutropenia in patients taking this drug and taking ACE inhibitors was 1.9% and 1.8% respectively. In clinical controlled trials, the incidence of significant increases in blood creatinine, blood potassium and total bilirubin in patients taking this drug was 0.8%, 4.4% and 6% respectively, while in the ACE inhibitor group it was 1.6%, 6.4% and 12.9% respectively. Patients taking this drug occasionally have elevated liver function indicators. No special laboratory indicators need to be monitored when this drug is used to treat patients with essential hypertension.

It is contraindicated for those who are known to be allergic to this product; it is contraindicated for pregnant and lactating women.

Precautions for children: There is no data on the efficacy and safety of this drug for children. Precautions for pregnancy and lactation: It is forbidden. Precautions for the elderly: See [Usage and Dosage] and [Precautions].

Clinical trials have not found clinically significant interactions between this drug and the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. This drug generally has no clinically significant interactions with metabolic inducers or inhibitors of the cytochrome P450 enzyme system. In vitro tests have shown that this drug has no plasma protein binding interactions with other drugs with high plasma protein binding rates, such as diclofenac, furosemide and warfarin. When used in combination with potassium-sparing diuretics (such as spironolactone, triamterene, amiloride), potassium preparations or potassium-containing salt substitutes, blood potassium may increase. If they must be used together, they should be monitored carefully.

Store in a dark, sealed and cool place (not exceeding 20°C).

80mg

24 months

Livzon (GROUP) Pharmaceutical FACTORY

• Founded in:

  1989-11-26

• Address:

  No. 38 Chuangye North Road, Jinwan District, Zhuhai City

• Tax NO.:

  91440400617489061P

• Registered Funds:

  450 million yuan

• Website:

  Log in to view

• Email:

  Log in to view